| Kerry Cooper |
Kerry Cooper is currently the Senior Vice President-Medical Affairs at Vera Therapeutics, Inc. Prior to this, Dr. Cooper held the position of Vice President-US Medical Affairs Renal Division at AstraZeneca PLC. From 2022 to 2023, Dr. Cooper served as the Senior Vice President-Medical Affairs at ProKidney Corp. Dr. Cooper completed their undergraduate degree at the University of Miami and obtained a doctorate degree from Yale School of Medicine. |
| Lauren Frenz |
Lauren Frenz is currently the Chief Business Officer at Vera Therapeutics, Inc. She started this position in 2020. Ms. Frenz has an MBA from Harvard Business School and an undergraduate degree from Princeton University. |
| Tom Doan |
Tom Doan has worked in the past and is currently employed at Vera Therapeutics, Inc. as a Senior Vice President-Development Operations since 2020. |
| Joseph Young |
Joseph Young is currently the Chief Accounting Officer & SVP-Finance at Vera Therapeutics, Inc. He previously worked as an Auditor at Ernst & Young LLP and as a Senior Vice President-Finance at Plexxikon, Inc. Mr. Young obtained his undergraduate degree from the University of California, Los Angeles and his MBA from the Haas School of Business. |
| Robert M. Brenner |
Robert M. Brenner is currently the Chief Medical Officer at Vera Therapeutics, Inc. He previously held positions as the President & Chief Executive Officer at AlloCure, Inc. in 2010, the Executive Director-Nephrology Medical Affairs at Amgen, Inc. from 1999 to 2008, the Senior Vice President-Medical Affairs at AMAG Pharmaceuticals, Inc. from 2008 to 2010, the Chief Medical Officer at Orionis Biosciences, Inc. from 2015 to 2018, and the Executive VP-Research & Development at Codiak BioSciences, Inc. from 2018 to 2019. He obtained his undergraduate degree from The Johns Hopkins University and his doctorate degree from Albert Einstein College of Medicine, Inc. |
| William D. Turner |
William D. Turner is currently the Chief Development Officer at Vera Therapeutics, Inc. Prior to his current position, he held the role of Senior Director-Regulatory Affairs at MedImmune Vaccines, Inc. and Medimmune, Inc. He also served as the Vice President-Regulatory Affairs at Dynavax Technologies Corp. from 2006 to 2009. From 2020 to 2022, he was the Chief Regulatory & Technical Operations Officer at Sierra Oncology, Inc. Before that, he worked as the SVP-Technical Operations & Regulatory at Aimmune Therapeutics, Inc. from 2018 to 2020. Mr. Turner completed his undergraduate degree at The California State University. |
| Sean P. Grant |
Sean P. Grant is currently the Chief Financial Officer at Vera Therapeutics, Inc. Prior to his current position, he served as the VP-Corporate Strategy & Business Development at CareDx, Inc. from 2020 to 2021. Before that, he was the Vice President-Investment Banking Healthcare at Citigroup, Inc. from 2015 to 2020. Mr. Grant completed his undergraduate degree at George Mason University and holds an MBA from Carey Business School. |
| Michael M. Morrissey |
Michael M. Morrissey's current job(s) include being the President, Chief Executive Officer & Director at Exelixis, Inc. since 2010, the Chairman at Vera Therapeutics, Inc. since 2022, and a Director at XWPharma Ltd. since 2020. Formerly, Dr. Morrissey served as a Director at CERo Therapeutics, Inc. from 2020 to 2022, a Senior Scientist at Ciba-Geigy Corp. from 1986 to 1991, and the Vice President-Discovery Research at Berlex Biosciences from 1991 to 2000. Dr. Morrissey holds a doctorate degree from Harvard University and an undergraduate degree from the University of Wisconsin. |
| Marshall W. Fordyce |
Marshall W. Fordyce is the founder of Vera Therapeutics, Inc. where he holds the title of President, Chief Executive Officer & Director since 2016. He is also the founder of Truecode Gene Repair, Inc. Marshall's current job is as a Non-Executive Director at Albert & Mary Lasker Foundation. Previously, he worked as a Senior Director-Clinical Research at Gilead Sciences, Inc. Marshall's education includes an undergraduate degree from Harvard University and a doctorate from Harvard Medical School. |
| Kimball Hall |
Kimball Hall is currently the Chief Executive Officer at Syntacoll Gmbh and the President & Chief Executive Officer at Innocoll Holdings Plc. She is also serving as an Independent Director at Vera Therapeutics, Inc. Previously, she held the position of President, Chief Operating Officer & Director at Abzena Ltd. and Senior Vice President at Genentech, Inc. From 2020 to 2023, she was the President & Chief Operating Officer at Abzena Holdings Us LLC. Ms. Hall completed her undergraduate degree at the University of Washington. |
| Scott William Morrison |
Scott William Morrison is an Independent Director at Corvus Pharmaceuticals, Inc., Zai Lab Ltd., IDEAYA Biosciences, Inc., Tarsus Pharmaceuticals, Inc., and Vera Therapeutics, Inc. He previously served as the Director of the Emerging Companies Section at the Biotechnology Innovation Organization, Director at Symic Bio, Inc., Director at The Bay Area Bioscience Association, Director & Treasurer at The Biotechnology Institute, and Partner at Ernst & Young LLP. He also held positions as an Independent Director at Global Blood Therapeutics, Inc., Astellas Gene Therapies, Inc., and ESCAPE Bio, Inc. Mr. Morrison received his undergraduate degree from the Haas School of Business. |
| Andrew Cheng |
Andrew Cheng is currently the President, Chief Executive Officer & Director at Akero Therapeutics, Inc., a Non-Executive Director at MorphoSys AG, an Independent Director at Vera Therapeutics, Inc., and a Director at Boys & Girls Clubs of Metro Los Angeles. He previously served as an Independent Director at Arbutus Biopharma Corp. from 2019 to 2022, and held positions as a Director at Syntimmune, Inc., a Director at Global Virus Network, and the Chief Medical Officer & Executive Vice President at Gilead Sciences, Inc. from 1999 to 2018. Dr. Cheng received his undergraduate degree from The Johns Hopkins University in 1988 and his doctorate from Columbia University College of Physicians & Surgeons in 1996. |
| Maha Katabi |
Maha Katabi is the founder of Oxalis Capital, Inc. She currently holds multiple director positions at Exactis Innovation, BIOTECanada, Ascendis Pharma, Inc., Quanta Therapeutics, Inc., Aerovate Therapeutics, Inc., Vera Therapeutics, Inc., Aiolos Bio, Inc., and Sofinnova Investments, Inc. She has also held director positions at Caprion Pharmaceuticals, Inc., RainDance Technologies, Inc., Apellis Pharmaceuticals, Inc., MacroGenics, Inc., Resonant Medical, Inc., F2G Ltd., NeurAxon, Inc., Amplyx Pharmaceuticals, Inc., eFFECTOR Therapeutics Operations, Inc., NorthSea Therapeutics BV, Rayzebio, Inc., Gyroscope Therapeutics Holdings Plc, Sectoral Asset Management, Inc., Ventures West Management, Inc., Transfer Technologies Commercialisation Capital, and Sectoral Asset Management Inc (Private Equity). Additionally, Dr. Katabi has a doctorate degree from McGill University and an undergraduate degree from McGill University. |
| Patrick G. Enright |
Patrick G. Enright founded Longitude Capital Management Co LLC in 2006, where he is working as Managing Director from 2006. Mr. Enright also currently works at Raven Biotechnologies, Inc., as Director, InfaCare Pharmaceutical Corp., as Director from 2006, Epirium Bio, Inc., as Director from 2019, and various other companies. Mr. Enright also formerly worked at Sequenom, Inc., as Director from 2006 to 2007, Esperion Therapeutics, Inc., as Independent Director from 2013 to 2016, Corcept Therapeutics, Inc., as Independent Director from 2011 to 2017, and various other companies. Mr. Enright received his undergraduate degree in 1984 from Stanford University and Masters Business Admin degree in 1989 from The Wharton School of the University of Pennsylvania. |
| Beth C. Seidenberg |
Beth C. Seidenberg is the founder and currently holds the position of Co-Founding Managing Director at Westlake Biopartners LLC, which was founded in 2018. She is also currently serving as Chairman at Kate Therapeutics, Inc., Director at Breathe Technologies, Inc., Independent Director at Sagimet Biosciences, Inc., Director at Auxogyn, Inc., Director at Mango Health, Inc., Director at Spruce Health, Inc., Lead Independent Director at Progyny, Inc., Director at Tmunity Therapeutics, Inc., Director at Cell Design Labs, Inc., Director at Expansion Therapeutics, Inc., Director at Arsenal Biosciences, Inc., Independent Director at Kyverna Therapeutics, Inc., Independent Director at Vera Therapeutics, Inc., Director at ACELYRIN, Inc., Director at Jamanda Ltd., Director at Electra Therapeutics, Inc., Director at Star Therapeutics, Inc., and Advisor at Kleiner Perkins Caufield & Byers LLC. She has previously held positions as Chairman at Arresto BioSciences, Inc. and Flexus Biosciences, Inc., Director at BioCryst Pharmaceuticals, Inc., Director at Tesaro, Inc., Director at RedBrick Health Corp., Independent Director at Epizyme, Inc., Director at iPierian, Inc., Director at Practice Fusion, Inc., Director at ARMO BioSciences, Inc., Director at True North Therapeutics, Inc., Independent Director at Atara Biotherapeutics, Inc., Director at Livongo Health, Inc., and Director at Rapt Therapeutics, Inc. She has also held the position of Senior Vice President at Amgen, Inc., Senior Vice President-Global Development at Bristol Myers Squibb Co., Vice President at Merck & Co., Inc., and VP-Immunology, Pulmonary & Dermatology at Merck Research Laboratories Massachusetts LLC. Additionally, she has worked as a Researcher at the National Institutes of Health. Dr. Seidenberg has an undergraduate degree from Barnard College and a doctorate degree from The University of Miami Leonard M. Miller School of Medicine. |
